Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.74 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.74 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6255154 | 0.85 | DPP4 (1.00) | DPP4DPP8DPP9 | |
| SCHEMBL23563035 | 0.78 | DPP4 (0.49) | DPP4DPP8DPP9 | |
| SCHEMBL5479978 | 0.78 | DPP4 (0.74) | DPP4DPP8DPP9 | |
| SCHEMBL24297255 | 0.77 | DPP4 (0.62) | DPP4DPP8DPP9 | |
| SCHEMBL6167534 | 0.76 | DPP4 (0.83) | DPP4DPP8DPP9 | |
| SCHEMBL14478379 | 0.74 | PREP (0.44) | DPP4DPP8DPP9 | |
| SCHEMBL18902439 | 0.74 | DPP4 (0.53) | DPP4DPP8DPP9 | |
| SCHEMBL5070864 | 0.74 | DPP4 (0.80) | DPP4DPP8DPP9 | |
| SCHEMBL1382238 | 0.72 | DPP4 (1.00) | DPP4DPP8DPP9 | |
| SCHEMBL648012 | 0.72 | DPP4 (1.00) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | MADAR DAVID J | 2007-10-11 | — | — | US | disclosed |
| US-7238724-B2 | Antidiabetic agents; hyperlipemic agents; obestity; immunomoderator; atherosclerosis | ABBOTT LABORATORIES (US) | 2007-07-03 | — | — | US | disclosed |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.